Holen Sie sich die Stockscreener-App
68.14
3.46%
-2.4895
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DXCM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$70.63
Offen:
$70.665
24-Stunden-Volumen:
6.61M
Relative Volume:
1.34
Marktkapitalisierung:
$26.73B
Einnahmen:
$4.30B
Nettoeinkommen (Verlust:
$571.50M
KGV:
47.70
EPS:
1.4285
Netto-Cashflow:
$570.80M
1W Leistung:
-2.24%
1M Leistung:
+1.62%
6M Leistung:
-4.20%
1J Leistung:
-5.43%
1-Tages-Spanne:
$66.42
$70.67
1-Wochen-Bereich:
$66.42
$72.08
52-Wochen-Spanne:
$57.52
$93.25
Dexcom Inc Stock (DXCM) Company Profile
Firmenname
Dexcom Inc
Sektor
Branche
Telefon
(858) 200-0200
Adresse
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Vergleichen Sie DXCM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
68.16 | 27.70B | 4.30B | 571.50M | 570.80M | 1.4285 |
|
ABT
Abbott Laboratories
|
126.58 | 221.35B | 43.84B | 13.94B | 6.78B | 7.9979 |
|
BSX
Boston Scientific Corp
|
101.25 | 151.78B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
377.56 | 146.70B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
93.59 | 120.73B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
82.41 | 47.45B | 5.69B | 1.41B | 577.90M | 6.9828 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Fortgesetzt | Stifel | Buy |
| 2025-09-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Eingeleitet | Argus | Buy |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-02-03 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-03-12 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2023-01-26 | Eingeleitet | Wolfe Research | Outperform |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-15 | Eingeleitet | Bernstein | Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-28 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-01-06 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-02 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Bestätigt | Piper Sandler | Overweight |
| 2020-05-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-11-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-10-23 | Eingeleitet | Stifel | Buy |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-19 | Hochstufung | Goldman | Sell → Neutral |
| 2018-09-12 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Bestätigt | Canaccord Genuity | Buy |
| 2018-07-02 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
| 2018-05-03 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-04 | Eingeleitet | Goldman | Sell |
| 2018-04-04 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Bestätigt | Wedbush | Outperform |
Alle ansehen
Dexcom Inc Aktie (DXCM) Neueste Nachrichten
DexCom Faces New Reports Of Deaths Linked To G7 Glucose Monitor - Benzinga
DexCom (DXCM) Shares Dip as Hunterbrook Issues Short Report - GuruFocus
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed DexCom, Inc. (DXCM) - GlobeNewswire Inc.
DexCom falls as Hunterbrook releases new short report (DXCM:NASDAQ) - Seeking Alpha
DexCom Shares Fall After Hunterbrook Report on Incidents Related to G7 Glucose Monitor - MarketScreener
Dexcom Shares Slide After Short Seller Flags 3 Additional Deaths From G7 Devices - Stocktwits
Dexcom (DXCM) Faces Scrutiny Following Reports of Glucose Monito - GuruFocus
DexCom (DXCM) Shares Fall 2% Following Short Report - GuruFocus
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Can Dexcom Deliver Strong Q3 Earnings on Stelo Gains and G7 Adoption? - TradingView
AstraZeneca non-executive director Euan Ashley joins DexCom board - Investing.com
AstraZeneca non-executive director Euan Ashley joins DexCom board By Investing.com - Investing.com UK
Will breakout in DexCom Inc. lead to full recovery2025 Analyst Calls & Fast Moving Market Watchlists - newser.com
Can technical indicators confirm DexCom Inc.’s reversalPortfolio Update Report & Free Expert Verified Stock Movement Alerts - newser.com
DexCom: Powering The Future Of Glucose Monitoring And Digital Care - RTTNews
What catalysts could drive DexCom Inc. stock higherTrade Exit Report & Consistent Profit Trading Strategies - newser.com
Is DexCom Inc. (DC4) stock a buy for dividend portfolios2025 Bull vs Bear & Expert-Curated Trade Recommendations - newser.com
DexCom Inc. stock daily chart insightsJuly 2025 Update & Safe Capital Allocation Plans - newser.com
Is DexCom Inc. stock reversal real or fakeMarket Growth Report & Risk Managed Investment Entry Signals - newser.com
DexCom Inc. stock chart pattern explainedWeekly Profit Analysis & AI Based Trade Execution Alerts - newser.com
What does recent volatility data suggest for DexCom Inc.Watch List & Fast Gaining Stock Strategy Reports - newser.com
Will DexCom Inc. stock maintain momentum in 2025Quarterly Trade Summary & AI Forecasted Entry and Exit Points - newser.com
Dexcom appoints Stanford’s Euan Ashley to board of directors - Investing.com
Dexcom appoints Stanford’s Euan Ashley to board of directors By Investing.com - Investing.com Nigeria
Dexcom appoints Euan Ashley to board of directors - MarketScreener
Dexcom Appoints Euan Ashley To Board Of Directors - TradingView
Dexcom Appoints Euan Ashley to Board of Directors - The Joplin Globe
DexCom, Inc. Experiences Valuation Adjustment Amidst Competitive Market Landscape - Markets Mojo
Halper Sadeh LLC Encourages DexCom, Inc. Shareholders to Contact the Firm to Discuss Their Rights - The AI Journal
Can DexCom Inc. stock sustain free cash flow growthTrade Analysis Report & Weekly High Return Stock Forecasts - newser.com
Is DexCom Inc. stock attractive for passive investorsDay Trade & Weekly Top Stock Performers List - newser.com
What MACD and RSI say about DexCom Inc.Portfolio Risk Summary & Free Technical Pattern Based Buy Signals - newser.com
Will a bounce in DexCom Inc. offer an exit2025 Volume Leaders & Long-Term Capital Growth Ideas - newser.com
What MACD trends signal for DexCom Inc. (DC4) stockEarnings Trend Report & Expert Approved Momentum Ideas - newser.com
Finanzdaten der Dexcom Inc-Aktie (DXCM)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.57%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):